Biocon announced today that its supplemental Biologics License Application (sBLA) for its biosimilar pegfilgrastim, Fulphila, filed with partner Mylan, has been approved by the FDA.
Biocon announced today that its supplemental Biologics License Application (sBLA) for its biosimilar pegfilgrastim, Fulphila, filed with partner Mylan, has been approved by the FDA.
The additional approval relates to Biocon’s new manufacturing facility for the biosimilar in Bengaluru, India. The FDA conducted its preapproval inspection of the new drug substance manufacturing facility from September 10 to September 19 of this year.
The new facility will allow Biocon and Mylan to scale up capacity “multi-fold,” said the company in a statement, to address the growing market for the biosimilar in the United States and around the world. Fulphila, the first biosimilar pegfilgrastim to launch in the United States commercially, currently competes with Coherus Biosciences’ Udencya and Sandoz’s Ziextenzo for a share of the brand-name Neulasta’s market.
Biocon’s chief executive officer, Christiane Hamacher, PhD, said in a statement announcing the sBLA’s approval that “This is a significant milepost in our journey,” and that the company expects to serve 5 million patients—and cross a revenue threshold of $1 billion—by financial year 2022. She also pointed to the benefits for the US healthcare system, saying that biosimilar penetration will enable better cost saving and greater patient access to high-quality treatment.
News of the progress for Fulphila comes shortly after Biocon announced that the FDA had issued an establishment inspection report for its Bengaluru facility and that the company would now be in a position to launch its long-awaited trastuzumab biosimilar, Ogivri, which is also approved by the FDA, “soon.”
Biocon, which also makes biosimilar insulins, has also recently announced its plans to improve access to high-quality insulins for patients with diabetes worldwide. As part of its universal access initiative, the company has said that it will offer human recombinant insulin at a cost of less than 10 cents per day for government procurement agencies in low- and middle-income countries.
Biocon will further discuss its access program during next week’s International Diabetes Federation Congress in Busan, South Korea.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.